NIOX Group Valuation
Is 82C undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 82C?
Other financial metrics that can be useful for relative valuation.
| What is 82C's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | UK£186.94m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.4x |
| Enterprise Value/EBITDA | 29.1x |
| PEG Ratio | -1.8x |
Price to Earnings Ratio vs Peers
How does 82C's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.7x | ||
FYB Formycon | 13.7x | 40.1% | €1.1b |
PSG PharmaSGP Holding | 31.2x | 12.8% | €343.2m |
B8F Biofrontera | 6.7x | 41.7% | €75.0m |
APPH Apontis Pharma | 31.3x | 46.5% | €84.1m |
82C NIOX Group | 13.3x | -7.5% | €186.9m |
Price to Earnings Ratio vs Industry
How does 82C's PE Ratio compare vs other companies in the European Biotechs Industry?
Price to Earnings Ratio vs Fair Ratio
What is 82C's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 13.3x |
| Fair PE Ratio | 8.6x |
Price-To-Earnings vs Fair Ratio: 82C is expensive based on its Price-To-Earnings Ratio (13.3x) compared to the estimated Fair Price-To-Earnings Ratio (8.6x).
Share Price vs Fair Value
What is the Fair Price of 82C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.48 | €0.62 +28.7% | 3.8% | €0.65 | €0.59 | n/a | 3 |
| Apr ’24 | €0.49 | €0.62 +26.0% | 3.8% | €0.65 | €0.59 | n/a | 3 |
| Mar ’24 | €0.51 | €0.56 +11.5% | 12.2% | €0.63 | €0.47 | n/a | 3 |
| Feb ’24 | €0.40 | €0.56 +40.8% | 12.2% | €0.63 | €0.47 | n/a | 3 |
| Jan ’24 | €0.38 | €0.55 +46.7% | 12.0% | €0.64 | €0.47 | n/a | 3 |
| Dec ’23 | €0.38 | €0.55 +45.9% | 12.0% | €0.64 | €0.47 | n/a | 3 |
| Nov ’23 | €0.40 | €0.55 +37.2% | 12.0% | €0.64 | €0.47 | n/a | 3 |
| Oct ’23 | €0.38 | €0.51 +33.2% | 6.8% | €0.54 | €0.47 | n/a | 2 |
| Sep ’23 | €0.37 | €0.53 +43.6% | 6.8% | €0.56 | €0.49 | n/a | 2 |
| Aug ’23 | €0.39 | €0.52 +33.8% | 6.8% | €0.56 | €0.49 | n/a | 2 |
| Jul ’23 | €0.36 | €0.55 +51.1% | 12.1% | €0.61 | €0.48 | n/a | 2 |
| Jun ’23 | €0.39 | €0.55 +39.5% | 12.1% | €0.61 | €0.48 | n/a | 2 |
| May ’23 | €0.40 | €0.55 +38.1% | 12.1% | €0.61 | €0.48 | n/a | 2 |
| Apr ’23 | €0.40 | €0.55 +36.8% | 12.1% | €0.61 | €0.48 | €0.49 | 2 |
| Mar ’23 | €0.43 | €0.48 +11.8% | 0% | €0.48 | €0.48 | €0.51 | 1 |
| Feb ’23 | €0.50 | €0.48 -4.3% | 0% | €0.48 | €0.48 | €0.40 | 1 |
| Jan ’23 | €0.46 | €0.48 +2.8% | 0% | €0.48 | €0.48 | €0.38 | 1 |
| Dec ’22 | €0.43 | €0.48 +11.9% | 0% | €0.48 | €0.48 | €0.38 | 1 |
| Apr ’22 | €0.32 | €0.25 -22.3% | 0% | €0.25 | €0.25 | €0.40 | 1 |